Cargando…
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Us...
Autores principales: | Addeo, Alfredo, Shah, Pankil K., Bordry, Natacha, Hudson, Robert D., Albracht, Brenna, Di Marco, Mariagrazia, Kaklamani, Virginia, Dietrich, Pierre-Yves, Taylor, Barbara S., Simand, Pierre-Francois, Patel, Darpan, Wang, Jing, Labidi-Galy, Intidhar, Fertani, Sara, Leach, Robin J., Sandoval, Jose, Mesa, Ruben, Lathrop, Kate, Mach, Nicolas, Shah, Dimpy P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218532/ https://www.ncbi.nlm.nih.gov/pubmed/34214473 http://dx.doi.org/10.1016/j.ccell.2021.06.009 |
Ejemplares similares
-
Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer
por: Bordry, Natacha, et al.
Publicado: (2021) -
Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
por: Terzic, Julie, et al.
Publicado: (2020) -
Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity
por: Lang, Noemie, et al.
Publicado: (2023) -
The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities
por: Zielli, Teresa, et al.
Publicado: (2023) -
Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review
por: Samartzis, Eleftherios P., et al.
Publicado: (2020)